GT Biopharma (GTBP) Price to Earnings (2010 - 2026)

GT Biopharma (GTBP) has reported Price to Earnings for 17 consecutive years, with 0.17 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Price to Earnings rose 39.36% year-over-year to 0.17 in Q1 2026; TTM through Mar 2026 was 0.02, a 17.04% increase from a year earlier, with the FY2025 full-year figure at 0.01, up 75.73% from the prior year.
• Price to Earnings was 0.17 for Q1 2026 at GT Biopharma, down from 0.02 in the prior quarter.
• Over five years, Price to Earnings peaked at 0.02 in Q3 2025 and troughed at 1.22 in Q2 2022.
• A 5-year average of 0.22 and a median of 0.14 in 2023 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings tumbled 357.65% in 2022 and surged 137.3% in 2025, its largest moves.
• Over 5 years, Price to Earnings stood at 0.2 in 2022, then grew by 28.57% to 0.14 in 2023, then soared by 49.61% to 0.07 in 2024, then soared by 68.09% to 0.02 in 2025, then plunged by 639.92% to 0.17 in 2026.
• The last three Price to Earnings figures came in at 0.17 (Q1 2026), 0.02 (Q4 2025), and 0.02 (Q3 2025), per Business Quant data.